ICAM1 and neoplasm: This cycle is based on CX3CL1/ICAM-1-mediated NSCLC cell-VBMEC interactions resulting in enhanced tumor cell aggressiveness and adhesion, improved VBMEC permeability, and increased NSCLC cell transendothelial migration through several signaling pathways.